NEW YORK, July 7 - Dutch microarray maker PamGene said today that it has raised €10 million ($11.4 million) in a second financing round led by LCF Rothschild Venture Partners.
Additional investors included Alta Partners, GIMV Venture Capital, and Life Sciences Partners. The new financing adds to a first-round investment of €6.7 million ($7.6 million) from these three firms in December 2000.
PamGene said the new funds would go toward development and marketing of its PamStation 96 microarray platform, which is scheduled to launch in the first quarter of 2004.
Raphael Wisniewski, investment manager at LCF Rothschild, will join PamGene's supervisory board, which is chaired by Jean Deleage of Alta Partners, and also includes Mark Wegter of LSP, Patrick van Beneden of GIMV, Ralph Martinke of Olympus, and Ton Stap of BioMerieux.